The global prostate cancer market size is estimated at USD 11.87 billion in 2024, grew to USD 12.88 billion in 2025 and is predicted to surpass around USD 26.84 billion by 2034, expanding at a CAGR of 8.50% between 2024 and 2034. The North America prostate cancer market size accounted for USD 5.34 billion in 2024 and is anticipated to grow at a fastest CAGR of 8.61% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prostate Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prostate Cancer Market Revenue and Volume, by Drug Class, 2024-2034
8.1.1. Hormonal ADT
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. AR-Directed Therapies
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Cytotoxic agents
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Bone metastases
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. therapeutic vaccines
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. PARP inhibitors
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Kinase inhibitors
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
8.1.8. PSMA-targeted radioligands
8.1.8.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Prostate Cancer Market Revenue and Volume, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Drug store & Retail pharmacies
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Online pharmacies
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Astellas Pharma, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca p
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Clovis Oncology, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dendreon Pharmaceuticals LLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Ferring Pharmaceuticals
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Johnson & Johnson (Janssen)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample